This review assessed the bronchoprotective effects of salmeterol or formeterol in patients with asthma who were using corticosteroid inhalers. The authors concluded that the beta2-agonists improved bronchoprotection compared with placebo. The evidence presented appears to support the authors' conclusions, but it is difficult to assess the generalisability of the results and the clinical importance of the findings is unknown.
Participants included in the review
Studies of asthmatic patients who were maintained on inhaled steroids were eligible for inclusion.
Outcomes assessed in the review
Studies that provoked bronchial constriction using direct (methacholine or histamine) or indirect (adenosine monophosphate) stimuli were eligible for inclusion. The primary outcome in the review was the doubling dose or dilution shift (i.e. the doubling dose/dilution of the stimulating agent that led to a 20% reduction in forced vital expiratory volume in one second).
